Alivus Life Sciences (ALIVUS) | Stock Overview & Key Data
Alivus Life Sciences Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹1,251.00 on February 3, 2025
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Alivus Life Sciences
ALIVUS
|
130.29B Mid-cap | -3.95% | -2.02% | 14.57% | 18.20% | 15.43% | 1.40% | -2.66% | -2.66% | -2.66% | -2.66% | -2.66% |
|
Sun Pharmaceutical
SUNPHARMA
|
3.88T Large-cap | -2.77% | -1.84% | 2.13% | -0.53% | 4.00% | 7.25% | 79.99% | 166.96% | 144.01% | 669.48% | 2,278.32% |
|
Divi's Laboratories
DIVISLAB
|
1.69T Large-cap | -3.26% | -1.31% | 2.02% | 1.80% | 2.98% | 0.83% | 89.86% | 56.44% | 484.44% | 1,625.50% | 9,907.51% |
|
Piramal Pharma
PPLPHARMA
|
199.68B Mid-cap | -6.68% | 4.13% | 9.23% | -9.90% | -1.74% | -16.24% | 115.91% | 3.17% | 3.17% | 3.17% | 3.17% |
|
Eris Lifesciences
ERIS
|
193.36B Mid-cap | 0.05% | 0.63% | 0.12% | -13.23% | -9.28% | -11.56% | 119.21% | 94.70% | 132.59% | 132.59% | 132.59% |
|
Neuland Laboratories
NEULANDLAB
|
184.81B Mid-cap | -0.95% | 4.87% | 29.12% | 3.39% | 12.28% | 48.55% | 510.11% | 716.28% | 2,058.53% | 16,354.50% | 19,900.00% |
Ownership & Short Interest
Calculate Your Alivus Life Sciences Investment Returns
Long-Term Investment Performance Analysis
Alivus Life Sciences stock price in Jan 2025 was ₹1,084.35, A ₹1,000.00 lump sum investment in Alivus Life Sciences made 1 years ago would be worth approximately ₹957.35 today, representing a negative return of -4.27%. This translates to an annualized return (CAGR) of -3.10%.
1 Year 4 Months Investment Scenario (Jan 2025 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is ALIVUS's 52-week high and low?
- In the last 52 weeks, Alivus Life Sciences reached a high of ₹1,148.40 (on May 11, 2026) and a low of ₹819.00 (on January 22, 2026).
- What is the market cap and P/E ratio for ALIVUS?
- Curious about Alivus Life Sciences's size and valuation? Its market capitalization stands at 130.29B. When it comes to valuation, the P/E ratio (trailing twelve months) is 23.91, and the forward P/E (looking ahead) is 20.89.
- Does ALIVUS pay dividends? If so, what's the yield?
- As for dividends, Alivus Life Sciences isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Alivus Life Sciences's main competitors or similar companies to consider before investing?
When looking at Alivus Life Sciences, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.88T Healthcare Drug Manufacturers - Specialty & Generic 7.25% 79.99% Divi's Laboratories
DIVISLAB1.69T Healthcare Drug Manufacturers - Specialty & Generic 0.83% 89.86% Piramal Pharma
PPLPHARMA199.68B Healthcare Drug Manufacturers - Specialty & Generic -16.24% 115.91% Eris Lifesciences
ERIS193.36B Healthcare Drug Manufacturers - Specialty & Generic -11.56% 119.21% Neuland Laboratories
NEULANDLAB184.81B Healthcare Drug Manufacturers - Specialty & Generic 48.55% 510.11% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Alivus Life Sciences Limited? (e.g., ROE, Debt/Equity)
- To get a sense of Alivus Life Sciences's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 17.24%, the Debt to Equity ratio from the most recent quarter is 2.01, and its Gross Profit Margin stands at 58.92%.
- What is the recent revenue and earnings growth for ALIVUS?
- Looking at Alivus Life Sciences's growth, its revenue over the trailing twelve months (TTM) was INR25B. Compared to the same quarter last year (YoY), quarterly revenue grew by 4.80%, and quarterly earnings saw a YoY growth of 9.70%.
- How much of ALIVUS stock is held by insiders and institutions?
- Wondering who owns Alivus Life Sciences stock? Company insiders (like executives and directors) hold about 76.10% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 7.86%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.